Given the high risk of adverse outcomes in patients with heart failure and reduced ejection
fraction (HFrEF), there is an urgent need for the initiation and titration of guideline-directed …

Hospitalization for major diabetes complications, including myocardial infarction, stroke,
lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a …

Importance Adoption of guideline-directed medical therapy for patients with heart failure is
variable. Interventions to improve guideline-directed medical therapy have failed to …

Background We investigated eligibility for dapagliflozin and empagliflozin in a real-world
heart failure (HF) cohort based on selection criteria of DAPA-HF (Dapagliflozin and …

Heart failure (HF) often coexists with insulin resistance (IR), and the incidence of HF in type
2 diabetes mellitus (T2DM) patients is significantly higher. The reciprocal relationship …

Background Acute heart failure (AHF) hospitalization presents an opportunity to optimize
pharmacotherapy to improve outcomes. Objectives This study's aim was to define eligibility …

Abstract Background In January 2021, vericiguat, a soluble guanylate cyclase stimulator,
was approved by the US Food and Drug Administration (FDA) to reduce the risk of …

Heart failure (HF) remains a leading cause of mortality and morbidity and a primary driver of
health care resource use in the United States. As such, there continues to be much interest …

Background The sodium–glucose co-transporter-2 (SGLT2) inhibitors dapagliflozin and
empagliflozin have been demonstrated to reduce adverse cardiovascular outcomes in …

ABSTRACT Background In the VerICiguaT Global Study in Subjects with Heart Failure with
Reduced Ejection Fraction (VICTORIA) trial, vericiguat reduced the risk of mortality due to …